Substance P-Mediated Vascular Protection Ameliorates Bone Loss

Figure 3

Systemic administration of SP prevents loss of angiogenic growth factors due to OVX within 4 weeks. (a) Experiment scheme for OVX and SP treatment. SP was injected intravenously twice a week for 4 weeks. Saline was used as vehicle control. (b) Change of rat body weight at 4 weeks was assessed. (c, d) Micro-CT analysis for quantification of bone density at 4 weeks post-OVX induction was carried out. (e) The representative images of Masson’s Trichrome staining of the femur. Scale bar: 100 μm. The amounts of VEGF (f), PDGF-BB (g), TNF- α (j), and IL-10 (k) in serum were measured by ELISA. The amounts of VEGF (h) and PDGF-BB (i) in BM were measured by ELISA. Values are SD, , , and . BV: trabecular bone volume; TV: tissue volume; BS: bone surface; n.s.: not significant.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)